Literature DB >> 12269772

Cyclo-oxygenase-2 expression in primary cancers of the lung and bladder compared to normal adjacent tissue.

Christopher J Sweeney1, Mark S Marshall, Darlene S Barnard, Douglas K Heilman, Steven D Billings, Liang Cheng, Steven J Marshall, Michele T Yip-Schneider.   

Abstract

Multiple observations in the laboratory and the clinical setting have linked expression of the enzyme cyclo-oxygenase-2 (COX-2) to carcinogenesis. The frequency and amount of COX-2 and Bcl-2 expression in primary lung and bladder cancer sites were detennined by immunoblot analysis of cell lysates prepared from frozen human tumor tissue and matched normal adjacent tissue. COX-2 protein was expressed statistically more frequently and at a higher level in primary adenocarcinomas and squamous cell carcinomas of the lung as well as transitional cell carcinomas of the bladder than in normal adjacent tissue. No correlation was observed between COX-2 and Bcl-2 expression in either the lung or bladder cancer specimens. Immunohistochemistry was also employed to localize COX-2 expression. In addition to expression in the malignant tissues, COX-2 was occasionally localized to the normal bronchial and transitional cell epithelia of the normal adjacent tissue. Detection of COX-2 in histologically normal appearing adjacent tissue suggests that COX-2 may be involved in early cellular changes leading to the development of lung and bladder cancer.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12269772     DOI: 10.1016/s0361-090x(02)00064-8

Source DB:  PubMed          Journal:  Cancer Detect Prev        ISSN: 0361-090X


  2 in total

1.  Increased COX-2 Immunostaining in Urothelial Carcinoma of the Urinary Bladder Is Associated with Invasiveness and Poor Prognosis.

Authors:  Basim Al-Maghrabi; Wafaey Gomaa; Mohammed Abdelwahed; Jaudah Al-Maghrabi
Journal:  Anal Cell Pathol (Amst)       Date:  2019-04-21       Impact factor: 2.916

2.  COX-2 overexpression in resected pancreatic head adenocarcinomas correlates with favourable prognosis.

Authors:  Ewa Pomianowska; Aasa R Schjølberg; Ole Petter F Clausen; Ivar P Gladhaug
Journal:  BMC Cancer       Date:  2014-06-20       Impact factor: 4.430

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.